N/A
N=156
Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Bottom Line
View on ClinicalTrials.gov: NCT01192282 ↗Enrolled (actual)
156
Serious AEs
0.0%
Results posted
Jan 2013
Primary outcome: Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Medical / Surgical Treatment (Procedure)
- Age
- Pediatric, Adult, Older Adult
- Sex
- Female
- Sponsor
- University of Cape Town
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HPV DNA and HIV Status |
96; 19; 4; 5; 2; 0 | — |
| PRIMARY HPV DNA and Pap Smear Results |
42; 5; 59; 2; 10; 0 | — |
| PRIMARY Number of HPV Genotypes Isolated by HIV Status |
44; 14; 1; 12; 1; 2 | — |
| PRIMARY Commonest HPV Genotypes Isolated by HIV Status |
46; 10; 33; 9; 19; 0 | — |
Summary
This is a longitudinal observational study of women presenting to Groote Schuur Hospital with genital warts. The study will evaluate the socio-demographic characteristics of the women using a structured questionnaire. It will also document the site and extend of the genital warts and genotyping will be performed on the warts. HIV status will be determined with patient consent, treatment modalities will be documented as will the outcome of treatment over a 6 month's period. Risk factors for recurrence or failure of treatment will be analysed as will the costs of treating women with genital warts.
Eligibility Criteria
Inclusion Criteria
- All female patients with genital warts
Exclusion Criteria
- Patients who are pregnant, too frail or ill for gynaeoclogical examination and refusal to participate
Data sourced from ClinicalTrials.gov (NCT01192282). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.